ZURICH, SWITZERLAND – Vaccentis, a biotech company based in Zurich, has announced a promising new partnership with TrueMed, a leading commercialization partner. The partnership will focus on the development of Vaccentis’ lead vaccine candidate VCC-001 and its platform technology, with the goal of accelerating the progress of cancer vaccines against renal cell carcinoma.
The partnership was solidified with a letter of intent, which outlines TrueMed’s support for Vaccentis in terms of research and development, as well as commercialization and distribution of VCC-001 and future pipeline candidates in Israel. This exclusive agreement will be in effect for the duration of the partnership.
The collaboration between Vaccentis and TrueMed brings together two companies with complementary expertise and resources. By combining Vaccentis’ research and expertise with TrueMed’s comprehensive competence in business development, investor relations, and strategic alliances, the hope is to significantly advance the next milestones for VCC-001.
Both companies are excited about the potential of this partnership and the opportunities it will bring.
“VCC-001 is a promising immune therapy approach with enormous potential to fundamentally improve the treatment of cancer,” say Arie Koren and Shmulik Berkovich, co-CEOs and founders of TrueMed. “With our many years of experience in market launch and commercialization, as well as our large investor network, we want to contribute to supporting Vaccentis in bringing the vaccine to patients as soon as possible.”
Vaccentis CEO Martin Munte and Vaccentis Member of the Board Patrik Grandits also express their enthusiasm for the collaboration: “TrueMed’s support for our mission offers valuable opportunities to further accelerate the development of our product candidate VCC-001 and tumor vaccine platform technology. Having a partner like TrueMed, with years of expertise and a large network in the health-related financial community, will be instrumental in bringing VCC-001 to patients in a timely manner.”
This partnership marks an important step forward for Vaccentis, a company that specializes in the development and manufacturing of individual cancer vaccines. Their focus is on the production of therapeutic individualized tumor vaccines from the patient’s own tumor, with an initial focus on renal cell carcinoma and plans to expand to other indications in the future. Vaccentis is expecting approval for the EU and USA in the coming years.
TrueMed, a leading commercialization partner for rare disease and specialty care therapies in Israel, is dedicated to providing global innovators with a tailored, turnkey “port-to-patient” solution. They have successfully partnered with leading U.S. and EU companies, launching locally some of the most innovative technologies and delivering complex therapies to patients in great need.
Both companies are confident that this partnership will bring great success and ultimately benefit patients in need of new and innovative treatments. For more information about Vaccentis, please visit vaccentis.com. To learn more about TrueMed, visit www.TrueMedtx.com.
For media inquiries, please contact Brandenstein Communications at +43 1 319 41 01-11 or presse@brandensteincom.at.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.